

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
05 January 2023 (05.01.2023)



(10) International Publication Number
WO 2023/274352 A1

(51) International Patent Classification:

C07K 16/00 (2006.01) C12N 5/10 (2006.01)
C07K 19/00 (2006.01) C07K 16/28 (2006.01)
C12N 15/62 (2006.01) A61K 39/395 (2006.01)
C12N 15/63 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/CN2022/102692

(22) International Filing Date:

30 June 2022 (30.06.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/CN2021/104201

02 July 2021 (02.07.2021)

CN

(71) Applicant: **LAEKNA THERAPEUTICS SHANGHAI CO., LTD.** [CN/CN]; 5th Floor, 987 Cailun Road, Zhangjiang, Pudong, Shanghai 201203 (CN).

(72) Inventors: **LU, Chris Xiangyang**; 15-502, 19 Kaibin Road, Xuhui District, Shanghai 200232 (CN). **GU, Xi-ang-Ju Justin**; 10-1901, Chuanhe Road, Pudong, Shanghai 201210 (CN). **ZHANG, Minhua**; 22-1202, 99 Dechun Road, Pudong, Shanghai 201210 (CN). **ZHANG, Ruipeng**; 3-1404, 376 Hangchang Road, Pudong, Shanghai 201317 (CN).

(74) Agent: **AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE**; Tower B, 21st Fl., Suite 2108, 38 Xueqing Road, Haidian, Beijing 100083 (CN).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: DEPLETION OF ACTIVATED HEPATIC STELLATE CELLS (HSCS) AND USES THEREOF

(57) Abstract: A binding molecule comprising a binding domain that binds to an antigen expressed on an activated hepatic stellate cells (HSC), and a functional domain that is capable of enhancing an antibody effector function such as antibody-dependent cell-mediated cytotoxicity (ADCC) toward activated HSCs. Uses of such binding molecule are also provided herein.

WO 2023/274352 A1